Terramera provides agricultural solutions aimed at reducing synthetic pesticides, increasing crop resiliency, predictability and quality, and supporting regenerative agronomy while measuring soil carbon. The company is advancing enrichSoil, a real-time soil analysis solution the article says delivers results with 99% accuracy and helps optimize fertilizer use. Once commercialized, enrichSoil is described as enabling farmers and agronomists to self-test nutrient levels including nitrogen (N), phosphorus (P), potassium (K) and carbon (C); its software optimizes sampling and supports variable-rate fertilizer application, with digital maps showing results across fields and over time. The company has launched an alpha product for EnrichAg through a strategic partnership with a large regenerative-agriculture network and is calibrating and iterating a beta product. An initial limited commercial launch is set for 2023 with further rollout and development planned throughout the year. The article identifies Karn Manhas as Founder & CEO and lists the company location as Vancouver, Canada. Terramera develops crop-protection products and a proprietary delivery mechanism called Actigate to boost the performance of biological and “natural” crop inputs. The company says Actigate can increase the efficacy of active ingredients such as bio-pesticides by up to 10x, making non-synthetic inputs more viable compared with synthetic chemicals. Terramera is positioning its technology to improve farm productivity, soil health and potential carbon sequestration. The latest capital raise will be used to advance and scale Actigate. The company frames its mission around transforming commercial agriculture and reducing reliance on chemical inputs. The articles describe the business and product focus but do not provide revenue or user metrics. Terramera's core product is Actigate™, a Targeted Performance technology that improves the performance of active ingredients used in crop protection, reducing the amount required. Actigate enhances both natural and conventional active ingredients, making organic biopesticides more effective and enabling reinvention of conventional inputs. The company says the technology lowers costs, improves farm productivity and profitability, reduces waste and minimizes environmental impact. Terramera aims to reduce global synthetic chemical loads in agriculture by 80% and increase global farm productivity by 20% by 2030. The privately held company was founded in 2010 and is headquartered in Vancouver, British Columbia, with integrated operations including a research lab, greenhouse and farm and an IP portfolio of more than 185 patents. It recently closed a Series B to scale the technology and accelerate its stated 2030 goals. Terramera develops technology-driven natural alternatives to conventional synthetic pesticides and fertilizers for farmers and consumers. The company uses science and R&D to commercialize plant-based products intended to increase agricultural yields while cutting synthetic chemical use. Terramera aims to increase global agriculture yields by 20% and reduce synthetic chemical load by 80% by 2028. The firm was named to the Global Cleantech 100 list for a second year and addresses an approximately USD $78-billion market for alternatives to conventional pesticides and fertilizers. Terramera plans to deploy financing to expand facilities, equipment, staffing and accelerate commercialization of its technologies. Karn Manhas is the company's Founder and CEO. Terramera applies a molecular delivery platform called Inspirium to existing bioactive materials to improve their performance. The Inspirium technology coats bioactives and ‘‘shuttles’’ them into pest cells, which the company says can increase efficacy three- to five-fold while improving stability and shelf-life. Terramera does not manufacture proprietary biopesticides; instead it combines its delivery technology with existing bioactives and will sell the combined products. Agricultural products are expected to be at least a year away from commercial shelves, but the company already sells a consumer bed‑bug product through Home Depot, which provides early revenue. The company holds EPA registrations and its team draws from agriculture and pharmaceutical backgrounds, with the technology influenced by drug-delivery techniques. Recent financing will support commercialization and go-to-market efforts, including partnerships with S2G portfolio companies.

Total raised

$75M

Funding rounds

5

Latest round

Equity

Latest activity

Jan 2023